Tonabacase is under clinical development by INtRON Biotechnology and currently in Phase I for Endocarditis. According to GlobalData, Phase I drugs for Endocarditis have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Tonabacase’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tonabacase (SAL-200) is under development for the treatment of staphylococcal aureus bacteremia (SAB), infective endocarditis (IE). The drug candidate is administered through intravenous route. SAL-200 is a new anti-bacterial enzyme (a bio-drug candidate). It contains recombinant SAL-1 as an active pharmaceutical ingredient. SAL-1 is a recombinant phage endolysin. The development of the drug candidate is based on the N-Rephasin technology.
It was under development for the treatment of methicillin-resistant staphylococcus aureus (MRSA) infections, vancomycin resistant staphylococcus aureus infections (VRSA), vancomycin-intermediate staphylococcus aureus (VISA), linezolid-resistant staphylococcus aureus (LRSA), linezolid-resistant MRSA (LR-MRSA), coagulase-negative Staphylococcus (CoNS)
INtRON Biotechnology overview
iNtRON Biotechnology (Intron Bio) is a drug development company. The company develops biotechnology and genetic engineering, which can be used to treat human diseases. Its technologies include endolysin, bacteriophage, biofilm and anti-cancer drug. The company’s endolysin technology is an antibiotic substance that destroys the cell walls of bacteria. Its the Moralbuster New Testament that can brings the dying to life. The company also develops infectious disease drugs. It conducts research and development for developing new drugs to treat various human diseases. The company has operations in Seongnam, Seoul and Daejeon, South Korea. Intron Bio is headquartered in Seongnam, South Korea.
For a complete picture of Tonabacase’s drug-specific PTSR and LoA scores, buy the report here.